Disease-modifying targets and strategies for Alzheimer's disease and Parkinson's disease

被引：0
|
作者：
Gao, Xiaoya [1 ,2 ]
机构：
[1] Southern Med Univ, Zhujiang Hosp, Dept Pediat Neurol, Guangzhou, Guangdong, Peoples R China
[2] Southern Med Univ, Zhujiang Hosp, Dept Neurol, Guangzhou, Guangdong, Peoples R China
来源：
FRONTIERS IN AGING NEUROSCIENCE | 2023年 / 15卷
关键词：
Alzheimer's disease; Parkinson's disease; disease modification; neuroprotection; novel targets; neurodegeneration;
D O I：
10.3389/fnagi.2023.1247256
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Disease-Modifying Treatments and Their Future in Alzheimer's Disease Management
    Smith, Blake
    Ownby, Raymond L.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (03)
  • [22] Huperzine A: is it an effective disease-modifying drug for Alzheimer's disease?
    Qian, Zhong Ming
    Ke, Ya
    FRONTIERS IN AGING NEUROSCIENCE, 2014, 6
  • [23] Therapeutic innovation in Parkinson's disease: a 2020 update on disease-modifying approaches
    Colombo, Daniele
    Pnevmatikou, Paraskevi
    Melloni, Elsa
    Keywood, Charlotte
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2020, 20 (10) : 1047 - 1064
  • [24] Biomarker candidates of neurodegeneration in Parkinson’s disease for the evaluation of disease-modifying therapeutics
    Manfred Gerlach
    Walter Maetzler
    Karl Broich
    Harald Hampel
    Lucas Rems
    Torsten Reum
    Peter Riederer
    Albrecht Stöffler
    Johannes Streffer
    Daniela Berg
    Journal of Neural Transmission, 2012, 119 : 39 - 52
  • [25] The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
    Craig W. Ritchie
    Tom C. Russ
    Sube Banerjee
    Bob Barber
    Andrew Boaden
    Nick C. Fox
    Clive Holmes
    Jeremy D. Isaacs
    Ira Leroi
    Simon Lovestone
    Matt Norton
    John O’Brien
    Jim Pearson
    Richard Perry
    James Pickett
    Adam D. Waldman
    Wai Lup Wong
    Martin N. Rossor
    Alistair Burns
    Alzheimer's Research & Therapy, 9
  • [26] Transthyretin as a therapeutic target: the future of disease-modifying therapies for Alzheimer’s disease
    Swetaleena Shaw
    Pratyush Porel
    Khadga Raj Aran
    Molecular Biology Reports, 2025, 52 (1)
  • [27] Assessing disease-modifying effects of norepinephrine in Down syndrome and Alzheimer's disease
    Ponnusamy, Ravikumar
    McNerney, M. Windy
    Moghadam, Shahrzad
    Salehi, Ahmad
    BRAIN RESEARCH, 2019, 1702 : 3 - 11
  • [28] Disease-Modifying Therapies for Alzheimer's Disease: More Questions than Answers
    Golde, Todd E.
    NEUROTHERAPEUTICS, 2022, 19 (01) : 209 - 227
  • [29] Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
    Todd E. Golde
    Neurotherapeutics, 2022, 19 : 209 - 227
  • [30] The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease
    Ritchie, Craig W.
    Russ, Tom C.
    Banerjee, Sube
    Barber, Bob
    Boaden, Andrew
    Fox, Nick C.
    Holmes, Clive
    Isaacs, Jeremy D.
    Leroi, Ira
    Lovestone, Simon
    Norton, Matt
    O'Brien, John
    Pearson, Jim
    Perry, Richard
    Pickett, James
    Waldman, Adam D.
    Wong, Wai Lup
    Rossor, Martin N.
    Burns, Alistair
    ALZHEIMERS RESEARCH & THERAPY, 2017, 9
12345